Exosome‐derived miR‐210 involved in resistance to osimertinib and epithelial–mesenchymal transition in EGFR mutant non‐small cell lung cancer cells

Exosome‐derived miR‐210 involved in resistance to osimertinib and epithelial–mesenchymal transition in EGFR mutant non‐small cell lung cancer cells

Abstract Background Osimertinib is a third‐generation epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) approved for the treatment of patients with EGFR‐mutant non‐small cell lung cancer (NSCLC). However, the mechanisms of acquired drug resistance to osimertinib have not as yet b...

Full description

Bibliographic Details
Main Authors: Kakeru Hisakane, Masahiro Seike, Teppei Sugano, Akiko Yoshikawa, Kuniko Matsuda, Natsuki Takano, Satoshi Takahashi, Rintaro Noro, Akihiko Gemma
Format: Article
Language:English
Published: Wiley 2021-06-01
Series:Thoracic Cancer
Subjects:
drug resistance
epithelial–mesenchymal transition
exosome
microRNA
osimertinib
Online Access:https://doi.org/10.1111/1759-7714.13943

Internet

https://doi.org/10.1111/1759-7714.13943

Similar Items